Reducing Diabetes Burden in Medtronic's Automated Insulin Delivery Systems
Diabetes Technology & Therapeutics · 2024-03 · 26 (3_suppl) · 7-16
DOI: 10.1089/dia.2023.0459 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Technology & Therapeutics, online erschienen am 05.02.2024. Verfasst von Gregory P Forlenza und 3 weiteren Autor:innen. Beteiligte Einrichtung: Barbara Davis Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
The MiniMed™ 780G advanced hybrid closed-loop system (MM780G) builds on the basal automation and low-glucose protection features of the MiniMed™ 670G and 770G systems. While previous publications have focused on glycemic control improvements with MM780G, burden reduction has not been fully described.
Methods
Data from two 3-month pivotal trials for the MM670G with Guardian™ Sensor 3 (GS3) (104 adults; 125 children) and MM780G with Guardian™ 4 Sensor (G4S) (67 adults;109 children) were compared. Real-world data (RWD) from United States users ( N = 3851) transitioning from MM770G+GS3 to MM780G+G4S were also analyzed. Analyses included a new metric for diabetes management burden (i.e., pentagon composite metric), glycemic outcomes and system burden (e.g., closed-loop exits and fingersticks per day).
Results
Diabetes burden metric (−22.8% and −28.5%), time in range (+3.1% [* P = 0.035] and +6.4% [ P < 0.001]) and time below range (−1.8% [* P < 0.001] and −0.7% [* P < 0.001]) significantly improved, compared to MM670G for adult and pediatric participants, respectively. The pediatric mean sensor glucose (SG) reduced by −8.6 mg/dL (* P < 0.001), while the adults' saw no change. Closed-loop use significantly increased for both cohorts (+17.1% [* P < 0.001] and +20.5% [* P < 0.001]). Closed-loop exits were significantly reduced to about 1 per week (−0.5 [* P < 0.001] and −0.7 [* P < 0.001]); fingerstick tests were also reduced (−6.2 [* P < 0.001] and −6.9 [* P < 0.001]). Similar outcomes were observed from U.S. RWD.
Conclusions
MiniMed™ 780G with G4S use was associated with significant reduction in diabetes management burden with fewer closed-loop exits, fingersticks and other interactions, and improvements in glycemic control when compared to the MiniMed™ 670G with GS3.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Barbara Davis Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Medtronic Diabetes, Northridge, California, USA.
ORCID-Profile: Gregory P Forlenza
Zitieren
APA
Forlenza, G. P., Dai, Z., Niu, F., & Shin, J. J. (2024). Reducing Diabetes Burden in Medtronic's Automated Insulin Delivery Systems. Diabetes Technology & Therapeutics, 26(3_suppl), 7-16. https://doi.org/10.1089/dia.2023.0459
Vancouver
Forlenza GP, Dai Z, Niu F, Shin JJ. Reducing Diabetes Burden in Medtronic's Automated Insulin Delivery Systems. Diabetes Technology & Therapeutics. 2024;26(3_suppl):7-16. doi:10.1089/dia.2023.0459
BibTeX
@article{Forlenza2024,
author = {Forlenza, Gregory P and Dai, Zheng and Niu, Fang and Shin, John J},
title = {Reducing Diabetes Burden in Medtronic's Automated Insulin Delivery Systems},
journal = {Diabetes Technology & Therapeutics},
year = {2024},
volume = {26},
number = {3_suppl},
pages = {7--16},
doi = {10.1089/dia.2023.0459}
}
EUVIMED